![A line drawing of a laptop and a cup of coffee](/sites/default/files/2020-12/hero-laptop.png)
This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.
This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.
This guide offers considerations for how state agency staff can develop and maintain an accessible, HIV and opioid use disorder (OUD) service inventory. This guide can be used by state agency HIV and OUD staff to:
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.
Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.
This webinar companion guide provides information for the January 2021 Strengthening Systems of Care: Supporting People with HIV and Opioid Use Disorder following Incarceration webinar.
This technical package, a collaborative effort between CDC and NASTAD, provides a broad framework as well as evidence-informed strategies and approaches to support the planning, design, implementation, and sustainability of new and existing syringe services programs (SSPs).